Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)
Key facts
- Where
- A Coruña, Barcelona, Madrid, Málaga, Pamplona, Sevilla és Valencia, SpanyolországSee the 12 sites
- Phase
- 2. fázis
Where in Spanyolország
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpanyolországNo longer taking part
- Hospital Universitari Vall d'HebronBarcelona, SpanyolországNo longer taking part
- Clinica Universidad de NavarraMadrid, SpanyolországNo longer taking part
- Hospital Clínico San CarlosMadrid, SpanyolországNo longer taking part
- Hospital Universitario 12 de OctubreMadrid, SpanyolországNo longer taking part
- Hospital Universitario Fundación Jiménez DíazMadrid, SpanyolországNo longer taking part
- Hospital Universitario Ramón y CajalMadrid, SpanyolországNo longer taking part
- Hospital Universitario Regional de MálagaMálaga, SpanyolországNo longer taking part
- Clínica Universidad de navarraPamplona, SpanyolországNo longer taking part
- University Hospital Virgen Del Rocio S.L.Sevilla, SpanyolországNo longer taking part
- Fundación Instituto Valenciano de OncologíaValencia, SpanyolországNo longer taking part
- Hospital Universitario Y Politecnico La FeValencia, SpanyolországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines Inc.
- Trial code
- EU 2025-521681-10-00
- Record updated
- 2026. augusztus 26.
- Original description
To evaluate the ORR as assessed by RECIST v1.1 criteria of zoldonrasib monotherapy in patients with RAS G12D-mutant NSCLC who have been previously treated with systemic therapyRead full original descriptionShow less
A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D
To evaluate the ORR as assessed by RECIST v1.1 criteria of zoldonrasib monotherapy in patients with RAS G12D-mutant NSCLC who have been previously treated with systemic therapy
Inclusion: Patients that are at least 18 years of age; Patients that have NSCLC with RAS-G12D mutation; Patients that have had cancer treatment before or are not able to tolerate regular treatments; Patients that have at least 1 measurable tumor (lesion); Patients that have adequate organ function (bone marrow, liver, kidney) and blood clotting.
Exclusion: Patients that have gastrointestinal problems that may affect absorption of the study drug medicine; Patients thathad any major surgery in the last 4 weeks; Patients that have previously taken targeted therapy for KRAS mutation; Patients that have any other medical condition that may interfere with the study medicine; Patient that have a history of severe allergic reactions to the study medicine; Patients that have primary brain and spinal cord tumor.